Regulatory affairs leads at rare disease companies use this agent when building the scientific and epidemiological case for Orphan Drug Designation at FDA OOPD or EMA COMP, where the prevalence threshold, plausibility of benefit, and medical plausibility arguments must each be rigorously substantiated with primary and secondary literature. Weak applications are refused on technical grounds that delay market exclusivity planning.